Institute of Pathology, Albert Szent-Györgyi Medical School, University of Szeged, 6725 Szeged, Hungary.
Centre of Excellence for Interdisciplinary Research, Development and Innovation University of Szeged, 6723 Szeged, Hungary.
Cells. 2022 Aug 31;11(17):2721. doi: 10.3390/cells11172721.
Breast cancer is the most frequent cancer with a high fatality rate amongst women worldwide. Diagnosing at an early stage is challenging, and due to the limitations of the currently used techniques, including mammography and imaging diagnostics, it still remains unascertained. Serum biomarkers can be a solution for this as they can be isolated in a less painful, more cost-effective, and minimally invasive manner. In this study, we shed light on the relevant role of multiple microRNAs (miRNAs) as potential biomarkers in breast cancer diagnosis. We monitored the expressional changes of 15 pre-selected miRNAs in a large cohort, including 65 patients with breast cancer and 42 healthy individuals. We performed thorough statistical analyses on the cohort sample set and determined the diagnostic accuracy of individual and multiple miRNAs. Our study reveals a potential improvement in diagnostics by implicating the monitoring of miR-15a+miR-16+miR-221 expression in breast cancer management.
乳腺癌是全球女性中发病率和死亡率最高的癌症。早期诊断具有挑战性，由于目前使用的技术（包括乳房 X 光摄影和影像学诊断）存在局限性，因此仍然无法确定。血清生物标志物可以解决这个问题，因为它们可以以更少的痛苦、更具成本效益和更小的创伤方式分离出来。在这项研究中，我们研究了多个 microRNAs（miRNAs）作为乳腺癌诊断潜在生物标志物的相关作用。我们监测了包括 65 名乳腺癌患者和 42 名健康个体在内的大队列中 15 个预选 miRNAs 的表达变化。我们对队列样本集进行了彻底的统计分析，并确定了单个和多个 miRNAs 的诊断准确性。我们的研究表明，通过监测 miR-15a+miR-16+miR-221 在乳腺癌管理中的表达，可以提高诊断的准确性。
